Singapore’s EUDA Launching Stem Cell Clinic in Shenzen, Upgrading Manufacturing Platform for iPSC and Immunotherapy

Key findings

• EUDA Health has launched a new stem cell therapy clinic in Shenzen.
• The company plans to upgrade Shenzhen Inno Immune’s cGMP facility to support iPSC-based work, stem cell processing, and immune cell therapies.

EUDA, a Singaporean non-invasive healthcare company, has launched new strategies for regenerative medicine in Asia.

They seem to be rolling out some of their recent moves, including a rights acquisition of T-cell therapies developed by a Chinese biotech company, Shenzhen Inno, and an announcement of their intention to acquire GO POSB Organoids, an iPSC development company also based in Singapore.

New Cell Therapy Production Center

As a part of that, they’re upgrading the Shenzen Inno cGMP manufacturing facility to create a “state-of-the-art production and innovation center” for stem cell therapies. EUDA stated that it will supply off-the-shelf iPSC therapies to hospitals, clinics, and biotech developers.

They’ll incorporate the existing Shenzen Inno iPSC platform with other IP from Japanese partners, such as Japan Early Light Medical Corporation, and the enhanced facility will support iPSC development and expansion, stem cell preparation, immune cell therapies, and the development of new treatments focused on immune health, skin health, and healthy aging. 

Shenzen’s New Clinic

Additionally, they’re launching a new Shenzen Longevity Clinic, saying “This clinic is strategically positioned to be the first in the region to comprehensively introduce Japanese longevity healthcare technologies,” and they’ll offer a portfolio of services including:

• Advanced stem cell and T-cell immunotherapies produced at the upgraded GMP facility in Shenzhen;
• Personalized AI-guided life cycle management; and
• Integrated Eastern, Western, and functional medicine.

The clinic will focus on enhancing longevity by slowing biological aging, strengthening immunity, and providing long-term health planning, supported by partnerships with leading longevity institutions and hospitals in Japan, the United States, and Singapore.

“This is a defining moment in EUDA’s evolution. By combining an iPSC platform, expanding stem cell and t-cell therapies, the new upgraded GMP facility’s production capacity, and a fully integrated longevity clinic, we are building a comprehensive, end-to-end regenerative ecosystem. Our robust partnerships with Shenzhen Inno, GO POSB, and the introduction of leading Japanese clinical expertise, positions EUDA to capitalize on the fast-growing longevity sector and operate at the frontier of healthcare.”

Want to keep up on regenerative medicine? Get the weekly newsletter here.